Bosentan for the treatment of adult pulmonary hypertension

Future Cardiology

Volumn 7, Issue 1, 2011, Pages 19-37

  Dwyer, Nathan ^a,b   Kilpatrick, David ^a,b  

^a ROYAL HOBART HOSPITAL   (Australia)

^b UNIVERSITY OF TASMANIA   (Australia)

Author keywords

antagonist; bosentan; endothelin; endothelin receptor; outcome; pulmonary arterial hypertension; pulmonary hypertension; treatment

Indexed keywords

AMBRISENTAN; AMIODARONE; BOSENTAN; CYCLOSPORIN A; ENDOTHELIN 1; FLUCONAZOLE; GLIBENCLAMIDE; ILOPROST; ITRACONAZOLE; KETOCONAZOLE; PROSTACYCLIN; SILDENAFIL; SIMVASTATIN; SITAXSENTAN; TADALAFIL; UNIPROST; VORICONAZOLE; WARFARIN;

ADD ON THERAPY; ANEMIA; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONGENITAL HEART DISEASE; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLUSHING; HEADACHE; HEART FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEG EDEMA; LIVER FUNCTION; MONOTHERAPY; PATHOGENESIS; PORTOPULMONARY HYPERTENSION; PRIORITY JOURNAL; PROTEIN FUNCTION; PULMONARY HYPERTENSION; SICKLE CELL ANEMIA; SIDE EFFECT;

ANTIHYPERTENSIVE AGENTS; COMORBIDITY; DISEASE PROGRESSION; ENDOTHELIN-1; EXERCISE TOLERANCE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; PROGNOSIS; QUALITY OF LIFE; RECEPTORS, ENDOTHELIN; SULFONAMIDES;

EID: 78650649961     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.10.114     Document Type: Article

References (137)

1. Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 54(1 Suppl. S), S55-S66 (2009).
2. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur. Heart J. 30(20), 2493-2537 (2009).
3. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 54(1 Suppl. 1), S43-S54 (2009).
4. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N. Engl. J. Med. 327(2), 76-81 (1992).
5. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111(23), 3105-3111 (2005).
6. Morrell NW, Adnot S, Archer SL, et al. Cellular and molecular basis of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 54(1 Suppl, 1), S20-S31 (2009).
7. Hassoun PM, Mouthon L, Barber JA, et al. Inflammation, growth factors, and pulmonary vascular remodeling. J. Am. Coll. Cardiol. 54(1 Suppl. 1), S10-S19 (2009).
8. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on expert consensus documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J. Am. Coll. Cardiol. 53(17), 1573-1619 (2009).
9. Keogh AM, Mayer E, Benza RL, et al. Interventional and surgical modalities of treatment in pulmonary hypertension. J. Am. Coll. Cardiol. 54(1 Suppl. 1), S67-S77 (2009).
10. Mereles D, Ehlken N, Kreuscher S, et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation 114(14), 1482-1489 (2006).
11. Rich S, Seidlitz M, Dodin E, et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest 114(3), 787-792 (1998).
12. Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 70(4), 580 (1984).
13. Motte S, McEntee K, Naeije R: Endothelin receptor antagonists. Pharmacol. Ther. 110(3), 386-414 (2006).
14. Davie N, Haleen SJ, Upton PD, et al. ETA and ETB receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am. J. Respir. Crit. Care Med. 165(3), 398-405 (2002). (Pubitemid 34118516)
15. Clozel M, Gray GA, Breu V, Lffler B, Osterwalder R: The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo. Biochem. Biophys. Res. Comm. 186(2), 867-873 (1992).
16. MacLean MR, McCulloch KM, Baird M. Endothelin ETA- and ETB-receptor-mediated vasoconstriction in rat pulmonary arteries and arterioles. J. Cardiovasc. Pharmacol. 23(5), 838-845 (1994).
17. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 328(24), 1732-1739 (1993). (Pubitemid 23170122)
18. Opitz CF, Ewert R, Kirch W, Pittrow D. Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter? Eur. Heart J. 29(16), 1936-1948 (2008).
19. Dupuis J, Goresky CA, Fournier A: Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors. J. Appl. Physiol. 81(4), 1510-1515 (1996).
20. de Nucci G, Thomas R, DOrleans-Juste P, et al. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc. Natl Acad. Sci. USA 85(24), 9797-9800 (1988).
21. Masaki T: Possible role of endothelin in endothelial regulation of vascular tone. Annu. Rev. Pharmacol. Toxicol. 35(1), 235-255 (1995).
22. Takahashi H, Soma S, Muramatsu M, et al. Discrepant distribution of big endothelin (ET)-1 and ET receptors in the pulmonary artery. Eur. Respir. J. 18(1), 5-14 (2001).
23. Soma S, Takahashi H, Muramatsu M, Oka M, Fukuchi Y: Localization and distribution of endothelin receptor subtypes in pulmonary vasculature of normal and hypoxia-exposed rats. Am. J. Respir. Cell Mol. Biol. 20(4), 620-630 (1999).
24. Abraham D, Vancheeswaran R, Dashwood M, et al. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am. J. Pathol. 151(3), 831-841 (1997). (Pubitemid 27385615)
25. Roux S, Breu V, Ertel SI, Clozel M. Endothelin antagonism with bosentan: a review of potential applications. J. Mol. Med. 77(4), 364-376 (1999).
26. Kim H, Yung GL, Marsh JJ, et al. Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension. Eur. Respir. J. 15(4), 640 (2000).
27. Chen SJ, Chen YF, Meng QC, et al. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J. Appl. Physiol. 79(6), 2122-2131 (1995).
28. Dingemanse J, Van Giersbergen P: Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin. Pharmacokinet. 43(15), 1089-1115 (2004).
29. Dhillon S, Keating GM. Bosentan: a review of its use in the management of mildly symptomatic pulmonary arterial hypertension. Am. J. Cardiovasc. Drugs 9(5), 331-350 (2009).
30. Dingemanse J, Bodin F, Weidekamm E, Kutz K, van Giersbergen P: Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. J. Clin. Pharmacol. 42(3), 283-289 (2002). (Pubitemid 34163474)
31. Weber C, Schmitt R, Birnboeck H, et al. Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers. J. Clin. Pharmacol. 39(7), 703-714 (1999).
32. Weber C, Gasser R, Hopfgartner G: Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects. Drug Metabol. Disposit. 27(7), 810-815 (1999).
33. Dingemanse J, van Giersbergen PLM. Influence of severe renal dysfunction on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. Int. J. Clin. Pharmacol. Ther. 40(7), 310-316 (2002). (Pubitemid 34732808)
34. van Giersbergen PLM, Popescu G, Bodin F, Dingemanse J. Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. J. Clin. Pharmacol. 43(1), 15-22 (2003).
35. Tracleer (bosentan). Full Prescribing Information. Actelion Pharmaceuticals US Inc.CA USA August (2009).
36. Treiber A, Schneiter R, Husler S, Stieger B: Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metabol. Disposit. 35(8), 1400-1407 (2007).
37. van Giersbergen PLM, Halabi A, Dingemanse J. Pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiol. Int. J. Clin. Pharmacol. Ther. 44(3), 113-118 (2006).
38. van Giersbergen PLM, Treiber A, Schneiter R, Dietrich H, Dingemanse J. Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects. Clin. Pharmacol. Ther. 81(3), 414-419 (2007).
39. Burgess G, Hoogkamer H, Collings L, Dingemanse J. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur. J. Clin. Pharmacol. 64(1), 43-50 (2008).
40. Gruenig E, Michelakis E, Vachiéry J, et al. Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 study. J. Clin. Pharmacol. 49(11), 1343-1352 (2009).
41. Galiè N, Rubin L, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a doubleblind, randomised controlled trial. Lancet 371(9630), 2093-2100 (2008).
42. Wrishko RE, Dingemanse J, Yu A, et al. Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. J. Clin. Pharmacol. 48(5), 610-618 (2008).
43. McRae MP, Lowe CM, Tian X, et al. Ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes. J. Pharmacol. Exp. Ther. 318(3), 1068-1075 (2006).
44. Dingemanse J, van Giersbergen PLM, Patat A, Nilsson PN. Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants. Antivir. Ther. (Lond.). 15(2), 157-163 (2010).
45. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo controlled study. Lancet 358(9288), 1119-1123 (2001). (Pubitemid 32971843)
46. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 346(12), 896-903 (2002).
47. Sitbon O, Badesch DB, Channick RN, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension. Chest 124(1), 247-254 (2003).
48. Jing Z, Strange G, Zhu X, et al. Efficacy, safety and tolerability of bosentan in Chinese patients with pulmonary arterial hypertension. J. Heart Lung Transplant. 29(2), 150-156 (2010).
49. Sohn D, Kim H, Kim M, et al. Beneficial and adverse effects of bosentan treatment in korean patients with pulmonary artery hypertension. Korean Circ. J. 39(3), 105-110 (2009).
50. Provencher S, Sitbon O, Humbert M, et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur. Heart J. 27(5), 589-595 (2006).
51. Denton CP, Pope JE, Peter H, et al. Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann. Rheum. Dis. 67(9), 1222-1228 (2008).
52. Keogh AM, McNeil KD, Wlodarczyk J, Gabbay E, Williams TJ. Quality of life in pulmonary arterial hypertension: improvement and maintenance with bosentan. J. Heart Lung Transplant. 26(2), 181-187 (2007).
53. Humbert M, Segal ES, Kiely DG, et al. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur. Respir. J. 30(2), 338-344 (2007).
54. Galiè N, Hinderliter AL, Torbicki A, et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension. J. Am. Coll. Cardiol. 41(8), 1380-1386 (2003).
55. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N. Engl. J. Med. 334(5), 296-301 (1996).
56. Steiner MK, Preston IR, Klinger JR, et al. Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension. Chest 130(5), 1471-1480 (2006).
57. Suleman N, Frost AE: Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension. Chest 126(3), 808-815 (2004).
58. Kim NH, Channick RN, Rubin LJ. Successful withdrawal of long-term epoprostenol therapy for pulmonary arterial hypertension. Chest 124(4), 1612-1615 (2003).
59. Launay D, Sitbon O, Le Pavec J, et al. Long-term outcome of systemic sclerosisassociated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology 49(3), 490-500 (2010).
60. Williams MH, Das C, Handler CE, et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 92(7), 926-932 (2006).
61. Joglekar A, Tsai FS, McCloskey DA, et al. Bosentan in pulmonary arterial hypertension secondary to scleroderma. J. Rheumatol. 33(1), 61-68 (2006).
62. Speich R, Jenni R, Opravil M, Pfab M, Russi EW. Primary pulmonary hypertension in HIV infection. Chest 100(5), 1268-1271 (1991).
63. Opravil M, Pechère M, Speich R, et al. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am. J. Respir. Crit. Care Med. 155(3), 990-995 (1997).
64. Sitbon O, Gressin V, Speich R, et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 170(11), 1212-1217 (2004).
65. Degano B, Yaici A, Le Pavec J, et al. Long-term effects of bosentan in patients with HIVassociated pulmonary arterial hypertension. Eur. Respir. J. 33(1), 92-98 (2009).
66. Galie N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 114(1), 48-54 (2006).
67. Gatzoulis MA, Beghetti M, Galiè N, et al. Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. Int. J. Cardiol. 127(1), 27-32 (2008).
68. Benza RL, Rayburn BK, Tallaj JA, et al. Efficacy of bosentan in a small cohort of adult patients with pulmonary arterial hypertension related to congenital heart disease. Chest 129(4), 1009-1015 (2006).
69. Iversen K, Jensen AS, Jensen TV, Vejlstrup NG, Søndergaard L: Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur. Heart J. 31(9), 1124-1131 (2010).
70. Kotlyar E, Sy R, Keogh AM, et al. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital cardiac disease. Cardiol. Young 16(03), 268-274 (2006).
71. Hoeper MM, Seyfarth HJ, Hoeffken G, et al. Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur. Respir. J. 30(6), 1096-1102 (2007).
72. Barst RJ, Mubarak KK, Machado RF, et al. Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies. Br. J. Haematol. 149(3), 426-435 (2010).
73. Minniti CP, Machado RF, Coles WA, et al. Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease. Br. J. Haematol. 147(5), 737-743 (2009).
74. Hoeper MM, Markevych I, Spiekerkoetter E, Welte T, Niedermeyer J. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur. Respir. J. 26(5), 858-863 (2005).
75. Humbert M, Barst R, Robbins I, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur. Respir. J. 24(3), 353-359 (2004). (Pubitemid 39232254)
76. Akagi S, Matsubara H, Miyaji K, et al. Additional effects of bosentan in patients with idiopathic pulmonary arterial hypertension already treated with high-dose epoprostenol. Circ. J. 72(7), 1142-1146 (2008).
77. Seyfarth H, Pankau H, Hammerschmidt S, et al. Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy. Chest. 128(2), 709-713 (2005).
78. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 174(11), 1257-1263 (2006).
79. Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur. Respir. J. 28(4), 691-694 (2006).
80. Hoeper M, Faulenbach C, Golpon H, et al. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur. Respir. J. 24(6), 1007-1010 (2004). (Pubitemid 39642293)
81. Mathai SC, Girgis RE, Fisher MR, et al. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur. Respir. J. 29(3), 469-475 (2007).
82. Galie N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 119(22), 2894-2903 (2009).
83. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J. Am. Coll. Cardiol. 55(18), 1915-1922 (2010).
84. Wilkins MR, Paul GA, Strange JW, et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am. J. Respir. Crit. Care Med. 171(11), 1292-1297 (2005).
85. Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J. Am. Coll. Cardiol. 47(10), 2049-2056 (2006).
86. Benza RL, Barst RJ, Galie N, et al. Sitaxsentan for the treatment of pulmonary arterial hypertension. Chest 134(4), 775-782 (2008).
87. Langleben D, Cacoub P: A review of STRIDE-2 and STRIDE-2X: the case for selective endothelin receptor blockade. Eur. J. Clin. Invest. 39, 27-31 (2009).
88. Roecker EB, Galie N, Olschewski H, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 117(23), 3010 (2008).
89. DAlonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann. Intern. Med. 115(5), 343-349 (1991).
90. Sandoval J, Bauerle O, Palomar A, et al. Survival in primary pulmonary hypertension. Validation of a prognostic equation. Circulation 89(4), 1733 (1994).
91. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension. Insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 122, 164-172 (2010).
92. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 122, 156-163 (2010).
93. McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur. Respir. J. 25(2), 244-249 (2005).
94. Denton C, Humbert M, Rubin L, Black C: Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann. Rheumat. Dis. 65(10), 1336-1340 (2006).
95. McLaughlin VV. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan. Eur. J. Clin. Invest. 36(S3), 10-15 (2006).
96. Girgis RE, Mathai SC, Krishnan JA, Wigley FM, Hassoun PM. Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases. J. Heart Lung Transplant. 24(10), 1626-1631 (2005).
97. Galiè N, Manes A, Negro L, et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur. Heart J. 30(4), 394-403 (2009).
98. Sitbon O, McLaughlin VV, Badesch DB, et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax 60(12), 1025-1030 (2005).
99. Jacobs W, Boonstra A, Brand M, et al. Long-term outcomes in pulmonary arterial hypertension in the first-line epoprostenol or first-line bosentan era. J. Heart Lung Transplant. 29(10), 1150-1158 (2010).
100. Keogh A, McNeil K, Williams TJ, et al. The bosentan patient registry: long-term survival in pulmonary arterial hypertension. Int. Med. J. DOI: 10.1111/j.1445-5994. 2009.02139.x (2010) (Epub ahead of print).
101. Packer M, McMurray J, Massie BM, et al. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J. Cardiac Fail. 11(1), 12-20 (2005).
102. Packer M. Effects of the endothelin receptor antagonist bosentan on the morbidity and mortality in patients with chronic heart failure: results of the ENABLE 1 and 2 trial program. Presented at: American College of Cardiology 51st Annual Scientific Session. Atlanta, GA, USA 17-20 March 2002.
103. Kalra PR, Moon JCC, Coats AJS. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int. J. Cardiol. 85(2-3), 195-197 (2002).
104. Teerlink JR: Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE): approaching the asymptote of efficacy? J. Cardiac Fail. 8(3), 124-127 (2002).
105. Kaluski E, Cotter G, Leitman M, et al. Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension; a multi-center randomized study. Cardiology 109(4), 273-280 (2008).
106. Perez-Villa F, Cuppoletti A, Rossel V, Vallejos I, Roig E: Initial experience with bosentan therapy in patients considered ineligible for heart transplantation because of severe pulmonary hypertension. Clin. Transplant. 20(2), 239-244 (2006).
107. Behr J, Ryu JH: Pulmonary hypertension in interstitial lung disease. Eur. Respir. J. 31(6), 1357-1367 (2008).
108. Chaouat A, Naeije R, Weitzenblum E: Pulmonary hypertension in COPD. Eur. Respir. J. 32(5), 1371-1385 (2008).
109. Stolz D, Rasch H, Linka A, et al. A randomised, controlled trial of bosentan in severe COPD. Eur. Respir. J. 32(3), 619-628 (2008).
110. Valerio G, Bracciale P, Grazia DAgostino A: Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease. Ther. Adv. Resp. Dis. 3(1), 15-21 (2009).
111. King TE, Behr J, Brown KK, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 177(1), 75-81 (2008).
112. Gunther A, Enke B, Markart P, et al. Safety and tolerability of bosentan in idiopathic pulmonary fibrosis: an open label study. Eur. Respir. J. 29(4), 713-719 (2007).
113. Seibold JR, Denton CP, Furst DE, et al. Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthrit. Rheumat. 62(7), 2101-2108 (2010).
114. Lang I: Advances in understanding the pathogenesis of chronic thromboembolic pulmonary hypertension. Br. J. Haematol. 149(4), 478-483 (2010).
115. Wittine LM, Auger WR: Chronic thromboembolic pulmonary hypertension. Curr. Treat. Options Cardiovasc. Med. 12(2), 131-141 (2010).
116. Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N. Engl. J. Med. 350(22), 2257-2264 (2004).
117. Becattini C, Agnelli G, Pesavento R, et al. Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism. Chest 130(1), 172-175 (2006).
118. Jamieson SW, Kapelanski DP, Sakakibara N, et al. Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. Ann. Thorac. Surg. 76(5), 1457-1462; discussion 1462-1464 (2003).
119. Jaïs X, DArmini AM, Jansa P, et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in Inoperable Forms of Chronic Thromboembolic Pulmonary Hypertension), a randomized, placebo-controlled trial. J. Am. Coll. Cardiol. 52(25), 2127-2134 (2008).
120. Hughes R, Jais X, Bonderman D, et al. The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study. Eur. Respir. J. 28(1), 138-143 (2006). (Pubitemid 44914271)
121. Becattini C, Manina G, Busti C, Gennarini S, Agnelli G: Bosentan for chronic thromboembolic pulmonary hypertension: findings from a systematic review and meta-analysis. Thromb. Res. 126(1), e51-e56 (2010).
122. EMA: Tracleer: EPAR - Summary for the Public. EMA, London, UK (2009).
123. Benza RL, Barst RJ, Galie N, et al. Sitaxsentan for the treatment of pulmonary arterial hypertension. Chest 134(4), 775-782 (2008).
124. Mano Y, Usui T, Kamimura H: Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance-associated protein 2. Biopharm. Drug Disposit. 28(1), 13-18 (2007).
125. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 169(4), 441-447 (2004).
126. Galie N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 117(23), 3010-3019 (2008).
127. Oudiz RJ, Galiè N, Olschewski H, et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 54(21), 1971-1981 (2009).
128. Lavelle A, Sugrue R, Lawler G, et al. Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension. Eur. Respir. J. 34(3), 770-771 (2009).
129. Hoeper MM, Olsson KM, Schneider A, Golpon H: Severe hepatitis associated with sitaxentan and response to glucocorticoid therapy. Eur. Respir. J. 33(6), 1518-1519 (2009).
130. Kenyon KW, Nappi JM. Bosentan for the treatment of pulmonary arterial hypertension. Ann Pharmacother. 37(7), 1055-1062 (2003).
131. Highland KB, Strange C, Mazur J, Simpson KN. treatment of pulmonary arterial hypertension. Chest 124(6), 2087-2092 (2003).
132. Garin MC, Clark L, Chumney ECG, Simpson KN, Highland KB: Cost-utility of treatments for pulmonary arterial hypertension. Clin. Drug Invest. 29(10), 635-646 (2009).
133. Wlodarczyk JH, Cleland LG, Keogh AM, et al. Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia: cost effectiveness and risk sharing. PharmacoEconomics 24(9), 903 (2006).
134. Stevenson MD, Macdonald FC, Langley J, Hunsche E, Akehurst R: The cost- effectiveness of bosentan in the United Kingdom for patients with pulmonary arterial hypertension of WHO functional class III. Value Health 12(8), 1100-1105 (2009).
135. Chen Y, Jowett S, Barton P, et al. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation. Health Technol. Assess. 13(49), 1-320 (2009).
136. Rich S, Herskowitz A: Targeting pulmonary vascular disease to improve global health. Chest 137(6 Suppl.), 1S-5S (2010).
137. Barst R, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 43(12 Suppl.), 40-47 (2004).